Latest news with #IambicTherapeutics
Yahoo
3 days ago
- Business
- Yahoo
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO, June 10, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. "While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials," said Tom Miller, PhD, Iambic's co-founder and CEO. "Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas." Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. "Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals." The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@
Business Wire
3 days ago
- Business
- Business Wire
Iambic Named to CNBC's 2025 Disruptor 50 List
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced today that it has been named to the annual CNBC Disruptor 50 list, which recognizes the most innovative private companies transforming industry. 'While many companies are building AI models for drug discovery, Iambic stands alone in terms of successfully and rapidly delivering new medicines to human clinical trials,' said Tom Miller, PhD, Iambic's co-founder and CEO. 'Our industry-leading models design breakthrough molecular structures that unlock challenging targets, de-risk development by predicting human response early in discovery, and accelerate the delivery of both first-in-class and best-in-class drug candidates across multiple disease areas.' Iambic's drug discovery platform integrates predictive modeling with automated experimentation, streamlining the pathway from discovery to clinical studies. Its lead oncology drug candidate went from program initiation to human trials in just two years, taking four years off the industry average, with a clinical data readout expected later this year. Independently and with partners, Iambic is advancing a pipeline of drug candidates for cancer and neurological diseases. Iambic recently announced advances to its two core AI drug discovery models. Enchant is the leading model for predicting clinical properties of potential drug molecules in humans, helping reduce the time, expense and risk of drug development. NeuralPLexer, which is used to predict the 3D structures of protein-ligand complexes, is faster and more accurate than AlphaFold3, giving researchers instant insights across protein classes and drug molecules to identify new drug candidates at unprecedented speed and scale. "We are working to redefine how medicines are discovered, developing AI and machine learning to increase efficiency by understanding the viability of new molecules before they enter pre-clinical and clinical studies, in turn reducing the time and cost of developing breakthrough treatments," said Fred Manby, PhD, Iambic's Chief Technology Officer and Co-Founder. 'Further, we are lowering clinical trial risk and patient burden by using AI to predict drug behavior before human testing and demonstrating how computational models can help regulators accelerate drug approvals.' The annual CNBC Disruptor 50 list showcases today's most forward-thinking and ambitious companies leading the way in innovation and industry transformation. Each submission underwent a thorough evaluation process, incorporating extensive research and analysis based on quantitative and qualitative metrics. Input from CNBC's editorial team and a diverse panel of entrepreneurial experts further informed the selection process. For the complete list of CNBC Disruptor 50 companies, visit About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at
Associated Press
28-05-2025
- Business
- Associated Press
Iambic Therapeutics to Participate in June Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--May 28, 2025-- Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following June investor conferences: About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: HEALTH TECHNOLOGY CLINICAL TRIALS ARTIFICIAL INTELLIGENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Iambic Therapeutics Copyright Business Wire 2025. PUB: 05/28/2025 07:30 AM/DISC: 05/28/2025 07:29 AM
Yahoo
28-05-2025
- Business
- Yahoo
Iambic Therapeutics to Participate in June Investor Conferences
SAN DIEGO, May 28, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following June investor conferences: Jefferies Global Healthcare Conference - June 3 - 5, 2025 UBS Spring Biotech Conference - June 24, 2025 About Iambic's AI-Driven Discovery Platform The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform's AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence. About Iambic Therapeutics Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at View source version on Contacts media@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
